Syndax Pharmaceuticals, Inc.

NasdaqGS:SNDX Rapporto sulle azioni

Cap. di mercato: US$1.8b

Syndax Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Syndax Pharmaceuticals Il CEO è Michael Metzger, nominato in Feb2022, e ha un mandato di 2.75 anni. la retribuzione annua totale è $ 9.13M, composta da 7.4% di stipendio e 92.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.062% delle azioni della società, per un valore di $ 1.14M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 8.3 anni.

Informazioni chiave

Michael Metzger

Amministratore delegato

US$9.1m

Compenso totale

Percentuale dello stipendio del CEO7.4%
Mandato del CEO2.8yrs
Proprietà del CEO0.06%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione8.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Aug 07

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Apr 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Michael Metzger rispetto agli utili di Syndax Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$297m

Jun 30 2024n/an/a

-US$264m

Mar 31 2024n/an/a

-US$241m

Dec 31 2023US$9mUS$678k

-US$209m

Sep 30 2023n/an/a

-US$176m

Jun 30 2023n/an/a

-US$160m

Mar 31 2023n/an/a

-US$153m

Dec 31 2022US$4mUS$640k

-US$149m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

US$818k

Mar 31 2022n/an/a

US$15m

Dec 31 2021US$3mUS$594k

US$25m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$91m

Mar 31 2021n/an/a

-US$86m

Dec 31 2020US$2mUS$577k

-US$77m

Sep 30 2020n/an/a

-US$71m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$3mUS$540k

-US$56m

Sep 30 2019n/an/a

-US$61m

Jun 30 2019n/an/a

-US$65m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$2mUS$506k

-US$74m

Sep 30 2018n/an/a

-US$74m

Jun 30 2018n/an/a

-US$72m

Mar 31 2018n/an/a

-US$67m

Dec 31 2017US$1mUS$492k

-US$61m

Compensazione vs Mercato: La retribuzione totale di Michael ($USD 9.13M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.38M ).

Compensazione vs guadagni: La retribuzione di Michael è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Michael Metzger (53 yo)

2.8yrs

Mandato

US$9,127,419

Compensazione

Mr. Michael A. Metzger is a Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer and as a member of the Boa...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Michael Metzger
CEO & Director2.8yrsUS$9.13m0.062%
$ 1.1m
Neil Gallagher
President1.6yrsUS$4.04m0.015%
$ 283.2k
Keith Goldan
CFO, Treasurer & Chief Accounting Officer2.4yrsUS$2.83m0.021%
$ 380.4k
Luke Albrecht
Senior VP8.3yrsUS$2.59m0.051%
$ 933.9k
Catherine Madigan
Chief Medical Officer2.7yrsUS$2.81m0.042%
$ 779.9k
Peter Ordentlich
Co-Founder & Chief Scientific Officer19.1yrsNessun dato0.00031%
$ 5.7k
Richard Heyman
Co-Founderno dataNessun datoNessun dato
Ronald Evans
Co-Founderno dataNessun datoNessun dato
Michael Downes
Co-Founderno dataNessun datoNessun dato
Sharon Klahre
Vice President of Investor Relations & Communications2.4yrsNessun datoNessun dato
Kevin McManus
Chief People Officer1.5yrsNessun datoNessun dato
Joseph Eder
Member of Scientific Advisory Board & Chief Medical Officer1.9yrsNessun datoNessun dato

2.4yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di SNDX è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Michael Metzger
CEO & Director5.3yrsUS$9.13m0.062%
$ 1.1m
Ronald Evans
Co-Founder8.3yrsNessun datoNessun dato
Joseph Eder
Member of Scientific Advisory Board & Chief Medical Officer8.3yrsNessun datoNessun dato
Keith Katkin
Independent Director7.7yrsUS$581.02k0.038%
$ 690.7k
Pierre Legault
Independent Director7.8yrsUS$575.59k0.038%
$ 690.7k
Dennis Podlesak
Independent Chairman15.9yrsUS$1.10m0.017%
$ 311.5k
George Sledge
Member of Scientific Advisory Board7.6yrsUS$23.05kNessun dato
Jedd D. Wolchok
Member of Scientific Advisory Board8.3yrsNessun datoNessun dato
Hope Rugo
Member of Scientific Advisory Board8.3yrsNessun datoNessun dato
Samir Khleif
Member of Scientific Advisory Board8.3yrsNessun datoNessun dato
Julie Brahmer
Member of Scientific Advisory Board8.9yrsNessun datoNessun dato
Lisa Coussens
Member of Scientific Advisory Board7.8yrsNessun datoNessun dato

8.3yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SNDX sono considerati esperti (durata media dell'incarico 8.3 anni).